Pharmacokinetics and pharmacodynamic effects of oral GLP-1 [glucagon-like-peptide-1] and PYY3-36 [peptide-YY-3-36]: a proof of concept study in healthy subjects
Phase of Trial: Phase I
Latest Information Update: 11 Jul 2007
At a glance
- Drugs Peptide YY 3-36 (Primary) ; Glucagon-like peptide-1
- Indications Diabetes mellitus; Heart failure; Obesity
- Focus Pharmacokinetics
- 11 Jul 2007 New trial record.